<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34930107</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1528-3658</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>Molecular medicine (Cambridge, Mass.)</Title><ISOAbbreviation>Mol Med</ISOAbbreviation></Journal><ArticleTitle>Risk surveillance and mitigation: autoantibodies as triggers and inhibitors of severe reactions to SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>160</StartPage><MedlinePgn>160</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">160</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s10020-021-00422-z</ELocationID><Abstract><AbstractText>COVID-19 clinical presentation differs considerably between individuals, ranging from asymptomatic, mild/moderate and severe disease which in some cases are fatal or result in long-term effects. Identifying immune mechanisms behind severe disease development informs screening strategies to predict who are at greater risk of developing life-threatening complications. However, to date clear prognostic indicators of individual risk of severe or long COVID remain elusive. Autoantibodies recognize a range of self-antigens and upon antigen recognition and binding, important processes involved in inflammation, pathogen defence and coagulation are modified. Recent studies report a significantly higher prevalence of autoantibodies that target immunomodulatory proteins including cytokines, chemokines, complement components, and cell surface proteins in COVID-19 patients experiencing severe disease compared to those who experience mild or asymptomatic infections. Here we discuss the diverse impacts of autoantibodies on immune processes and associations with severe COVID-19 disease.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Catherine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, 3052, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biology, The University of Melbourne, Melbourne, VIC, 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Amelia</LastName><ForeName>Aisah</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, 3052, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biology, The University of Melbourne, Melbourne, VIC, 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ashdown</LastName><ForeName>George W</ForeName><Initials>GW</Initials><AffiliationInfo><Affiliation>The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, 3052, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biology, The University of Melbourne, Melbourne, VIC, 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mueller</LastName><ForeName>Ivo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, 3052, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biology, The University of Melbourne, Melbourne, VIC, 3052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coussens</LastName><ForeName>Anna K</ForeName><Initials>AK</Initials><Identifier Source="ORCID">0000-0002-7086-2621</Identifier><AffiliationInfo><Affiliation>The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, 3052, Australia. coussens.a@wehi.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biology, The University of Melbourne, Melbourne, VIC, 3052, Australia. coussens.a@wehi.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathology, Institute of Infectious Disease and Molecular Medicine, Wellcome Centre for Infectious Diseases Research in Africa, University of Cape, Cape Town, South Africa. coussens.a@wehi.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eriksson</LastName><ForeName>Emily M</ForeName><Initials>EM</Initials><Identifier Source="ORCID">0000-0002-7851-973X</Identifier><AffiliationInfo><Affiliation>The Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, VIC, 3052, Australia. eriksson@wehi.edu.au.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Biology, The University of Melbourne, Melbourne, VIC, 3052, Australia. eriksson@wehi.edu.au.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>GNT1161627</GrantID><Agency>National Health and Medical Research Council</Agency><Country/></Grant><Grant><GrantID>GNT1043345</GrantID><Agency>National Health and Medical Research Council</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Med</MedlineTA><NlmUniqueID>9501023</NlmUniqueID><ISSNLinking>1076-1551</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015551" MajorTopicYN="N">Autoimmunity</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoantibodies</Keyword><Keyword MajorTopicYN="N">Autoimmunity</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>Authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>5</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34930107</ArticleId><ArticleId IdType="pmc">PMC8686808</ArticleId><ArticleId IdType="doi">10.1186/s10020-021-00422-z</ArticleId><ArticleId IdType="pii">10.1186/s10020-021-00422-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ali YM, Ferrari M, Lynch NJ, et al. Lectin pathway mediates complement activation by SARS-CoV-2 proteins. Front Immunol. 2021;12:714511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8287855</ArticleId><ArticleId IdType="pubmed">34290717</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Ramadan A, Rabab'h O, Shah J, et al. Acute and post-acute neurological complications of COVID-19. Neurol Int. 2021;13:102&#x2013;119.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8006051</ArticleId><ArticleId IdType="pubmed">33803475</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P, Rosen LB, Zhang Q, et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Bautista-Becerril B, Campi-Caballero R, Sevilla-Fuentes S, et al. Immunothrombosis in COVID-19: implications of neutrophil extracellular traps. Biomolecules. 2021;11:694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8148218</ArticleId><ArticleId IdType="pubmed">34066385</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulle A, Davies MA, Hussey H, et al. Risk factors for COVID-19 death in a population cohort study from the Western Cape Province. South Africa. Clin Infect Dis. 2020;7:e314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499501</ArticleId><ArticleId IdType="pubmed">32860699</ArticleId></ArticleIdList></Reference><Reference><Citation>Brodard J, Kremer Hovinga JA, Fontana P, et al. COVID-19 patients often show high-titer non-platelet-activating anti-PF4/heparin IgG antibodies. J Thromb Haemost. 2021;19:1294&#x2013;1298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8013750</ArticleId><ArticleId IdType="pubmed">33550713</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barre Syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet. 2016;387:1531&#x2013;1539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444521</ArticleId><ArticleId IdType="pubmed">26948433</ArticleId></ArticleIdList></Reference><Reference><Citation>Casciola-Rosen L, Thiemann DR, Andrade F, et al. IgM autoantibodies recognizing ACE2 are associated with severe COVID-19. medRxiv. 2020;323:2052.</Citation></Reference><Reference><Citation>Chang SE, Feng A, Meng W, et al. New-Onset IgG Autoantibodies in hospitalized patients with COVID-19. medRxiv. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8440763</ArticleId><ArticleId IdType="pubmed">34521836</ArticleId></ArticleIdList></Reference><Reference><Citation>de Nooijer AH, Grondman I, Janssen NAF, et al. Complement activation in the disease course of coronavirus disease 2019 and its effects on clinical outcomes. J Infect Dis. 2021;223:214&#x2013;224.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7797765</ArticleId><ArticleId IdType="pubmed">33038254</ArticleId></ArticleIdList></Reference><Reference><Citation>DelSole F, Farcomeni A, Loffredo L, et al. Features of severe COVID-19: a systematic review and meta-analysis. Eur J Clin Invest. 2020;50:e13378.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7435565</ArticleId><ArticleId IdType="pubmed">32860457</ArticleId></ArticleIdList></Reference><Reference><Citation>Englert H, Rangaswamy C, Deppermann C, et al. Defective NET clearance contributes to sustained FXII activation in COVID-19-associated pulmonary thrombo-inflammation. EBioMedicine. 2021;67:103382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8120108</ArticleId><ArticleId IdType="pubmed">34000623</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang X, Li S, Yu H, et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. Aging (albany NY) 2020;12:12493&#x2013;12503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7377860</ArticleId><ArticleId IdType="pubmed">32658868</ArticleId></ArticleIdList></Reference><Reference><Citation>Finsterer J, Scorza FA. Guillain-Barre syndrome in 220 patients with COVID-19. Egypt J Neurol Psychiatr Neurosurg. 2021;57:55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8094972</ArticleId><ArticleId IdType="pubmed">33967575</ArticleId></ArticleIdList></Reference><Reference><Citation>Flint SM, McKinney EF, Smith KG. Emerging concepts in the pathogenesis of antineutrophil cytoplasmic antibody-associated vasculitis. Curr Opin Rheumatol. 2015;27:197&#x2013;203.</Citation><ArticleIdList><ArticleId IdType="pubmed">25629443</ArticleId></ArticleIdList></Reference><Reference><Citation>Franke C, Ferse C, Kreye J, et al. High frequency of cerebrospinal fluid autoantibodies in COVID-19 patients with neurological symptoms. Brain Behav Immun. 2021;93:415&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7834471</ArticleId><ArticleId IdType="pubmed">33359380</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T, Knight M, A&#x2019;Court C, et al. Management of post-acute COVID-19 in primary care. BMJ. 2020;370:3026.</Citation><ArticleIdList><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Greinacher A, Thiele T, Warkentin TE, et al. Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med. 2021;384:2092&#x2013;2101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8095372</ArticleId><ArticleId IdType="pubmed">33835769</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55:2001227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7098485</ArticleId><ArticleId IdType="pubmed">32217650</ArticleId></ArticleIdList></Reference><Reference><Citation>Holter JC, Pischke SE, de Boer E, et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc Natl Acad Sci USA. 2020;117:25018&#x2013;25025.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7547220</ArticleId><ArticleId IdType="pubmed">32943538</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang L, Yao Q, Gu X, et al. 1-Year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. Lancet. 2021;398:747&#x2013;758.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8389999</ArticleId><ArticleId IdType="pubmed">34454673</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JJL. Persistent SARS-2 infections contribute to long COVID-19. Med Hypotheses. 2021;149:110538.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884250</ArticleId><ArticleId IdType="pubmed">33621843</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs BC, Rothbarth PH, van der Meche FG, et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology. 1998;51:1110&#x2013;1115.</Citation><ArticleIdList><ArticleId IdType="pubmed">9781538</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayarangaiah A, Kariyanna PT, Chen X, et al. COVID-19-associated coagulopathy: an exacerbated immunothrombosis response. Clin Appl Thromb Hemost. 2020;26:1076029620943293.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7401047</ArticleId><ArticleId IdType="pubmed">32735131</ArticleId></ArticleIdList></Reference><Reference><Citation>Khamsi R. Rogue antibodies could be driving severe COVID-19. Nature. 2021;590:29&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">33469204</ArticleId></ArticleIdList></Reference><Reference><Citation>Leonhard SE, Bresani-Salvi CC, Lyra Batista JD, et al. Guillain-Barre syndrome related to Zika virus infection: a systematic review and meta-analysis of the clinical and electrophysiological phenotype. PLoS Negl Trop Dis. 2020;14:e0008264.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7205322</ArticleId><ArticleId IdType="pubmed">32339199</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez J, Mommert M, Mouton W, et al. Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs. J Exp Med 2021;218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8352718</ArticleId><ArticleId IdType="pubmed">34357402</ArticleId></ArticleIdList></Reference><Reference><Citation>Lourda M, Dzidic M, Hertwig L, et al. High-dimensionalprofilingreveals phenotypic heterogeneity and disease-specific 1alterationsof granulocytesin COVID-19. medRxiv. 2021;146:119.</Citation></Reference><Reference><Citation>Lucchese G, Floel A. SARS-CoV-2 and Guillain-Barre syndrome: molecular mimicry with human heat shock proteins as potential pathogenic mechanism. Cell Stress Chaperones. 2020;25:731&#x2013;735.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7387880</ArticleId><ArticleId IdType="pubmed">32729001</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantej J, Bednarek M, Sitko K, et al. Autoantibodies to heat shock protein 60, 70, and 90 are not altered in the anti-SARS-CoV-2 IgG-seropositive humans without or with mild symptoms. Cell Stress Chaperones. 2021;26:735&#x2013;740.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8172177</ArticleId><ArticleId IdType="pubmed">34080135</ArticleId></ArticleIdList></Reference><Reference><Citation>Manz MG, Boettcher S. Emergency granulopoiesis. Nat Rev Immunol. 2014;14:302&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pubmed">24751955</ArticleId></ArticleIdList></Reference><Reference><Citation>McGrath FD, Brouwer MC, Arlaud GJ, et al. Evidence that complement protein C1q interacts with C-reactive protein through its globular head region. J Immunol. 2006;176:2950&#x2013;2957.</Citation><ArticleIdList><ArticleId IdType="pubmed">16493053</ArticleId></ArticleIdList></Reference><Reference><Citation>McMillan P, Uhal BD. COVID-19&#x2014;a theory of autoimmunity to ACE-2. MOJ Immunol. 2020;7:17&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7351250</ArticleId><ArticleId IdType="pubmed">32656314</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton EA, He XY, Denorme F, et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020;136:1169&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7472714</ArticleId><ArticleId IdType="pubmed">32597954</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakazawa D, Masuda S, Tomaru U, et al. Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol. 2019;15:91&#x2013;101.</Citation><ArticleIdList><ArticleId IdType="pubmed">30542206</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazy I, Jevtic SD, Moore JC, et al. Platelet-activating immune complexes identified in critically ill COVID-19 patients suspected of heparin-induced thrombocytopenia. J Thromb Haemost. 2021;19:1342&#x2013;1347.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8014456</ArticleId><ArticleId IdType="pubmed">33639037</ArticleId></ArticleIdList></Reference><Reference><Citation>Nemeth T, Sperandio M, Mocsai A. Neutrophils as emerging therapeutic targets. Nat Rev Drug Discov. 2020;19:253&#x2013;275.</Citation><ArticleIdList><ArticleId IdType="pubmed">31969717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng LG. Neutrophil: a mobile fertilizer. J Exp Med. 2019;216:4&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6314528</ArticleId><ArticleId IdType="pubmed">30567720</ArticleId></ArticleIdList></Reference><Reference><Citation>Ng LG, Ostuni R, Hidalgo A. Heterogeneity of neutrophils. Nat Rev Immunol. 2019;19:255&#x2013;265.</Citation><ArticleIdList><ArticleId IdType="pubmed">30816340</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen TH, Medvedev N, Delcea M, et al. Anti-platelet factor 4/polyanion antibodies mediate a new mechanism of autoimmunity. Nat Commun. 2017;8:14945.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5458132</ArticleId><ArticleId IdType="pubmed">28530237</ArticleId></ArticleIdList></Reference><Reference><Citation>Organization WH. 2021. https://www.who.int/publications/i/item/clinical-management-of-covid-19.</Citation></Reference><Reference><Citation>Pillay J, den Braber I, Vrisekoop N, et al. In vivo labeling with 2H2O reveals a human neutrophil lifespan of 5.4 days. Blood. 2010;116:625&#x2013;627.</Citation><ArticleIdList><ArticleId IdType="pubmed">20410504</ArticleId></ArticleIdList></Reference><Reference><Citation>Rambaldi A, Gritti G, Mico MC, et al. Endothelial injury and thrombotic microangiopathy in COVID-19: treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology. 2020;225:152001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7415163</ArticleId><ArticleId IdType="pubmed">32943233</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiff DD, Meyer CG, Marlin B, et al. New onset ANCA-associated vasculitis in an adolescent during an acute COVID-19 infection: a case report. BMC Pediatr. 2021;21:333.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8338201</ArticleId><ArticleId IdType="pubmed">34353302</ArticleId></ArticleIdList></Reference><Reference><Citation>Reusch N, De Domenico E, Bonaguro L, et al. Neutrophils in COVID-19. Front Immunol. 2021;12:652470.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8027077</ArticleId><ArticleId IdType="pubmed">33841435</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2007;25:1265&#x2013;1275.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2966895</ArticleId><ArticleId IdType="pubmed">17989689</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Perez AI, Labandeira CM, Pedrosa MA, et al. Autoantibodies against ACE2 and angiotensin type-1 receptors increase severity of COVID-19. J Autoimmun. 2021;122:102683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8193025</ArticleId><ArticleId IdType="pubmed">34144328</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyaolu A, Okorie C, Marinkovic A, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020;2:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7314621</ArticleId><ArticleId IdType="pubmed">32838147</ArticleId></ArticleIdList></Reference><Reference><Citation>Scapini P, Marini O, Tecchio C, et al. Human neutrophils in the saga of cellular heterogeneity: insights and open questions. Immunol Rev. 2016;273:48&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">27558327</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiaffino MT, Di Natale M, Garcia-Martinez E, et al. Immunoserologic detection and diagnostic relevance of cross-reactive autoantibodies in coronavirus disease 2019 patients. J Infect Dis. 2020;222:1439&#x2013;1443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454719</ArticleId><ArticleId IdType="pubmed">32738141</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulte-Schrepping J, Reusch N, Paclik D, et al. Severe COVID-19 is marked by a dysregulated myeloid cell compartment. Cell. 2020;182:1419&#x2013;1440e23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7405822</ArticleId><ArticleId IdType="pubmed">32810438</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully M, Singh D, Lown R, et al. Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination. N Engl J Med. 2021;384:2202&#x2013;2211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8112532</ArticleId><ArticleId IdType="pubmed">33861525</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestre-Roig C, Hidalgo A, Soehnlein O. Neutrophil heterogeneity: implications for homeostasis and pathogenesis. Blood. 2016;127:2173&#x2013;2181.</Citation><ArticleIdList><ArticleId IdType="pubmed">27002116</ArticleId></ArticleIdList></Reference><Reference><Citation>Study ZC. 2021. https://covid.joinzoe.com/post/new-top-5-covid-symptoms.</Citation></Reference><Reference><Citation>Tak T, Tesselaar K, Pillay J, et al. What&#x2019;s your age again? Determination of human neutrophil half-lives revisited. J Leukoc Biol. 2013;94:595&#x2013;601.</Citation><ArticleIdList><ArticleId IdType="pubmed">23625199</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Wijst MGP, Vazquez SE, Hartoularos GC, et al. Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Sci Transl Med. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8601717</ArticleId><ArticleId IdType="pubmed">34429372</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallukat G, Hohberger B, Wenzel K, et al. Functional autoantibodies against G-protein coupled receptors in patients with persistent Long-COVID-19 symptoms. J Transl Autoimmun. 2021;4:100100.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8049853</ArticleId><ArticleId IdType="pubmed">33880442</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y, Jonsson F. Expression, role, and regulation of neutrophil fcgamma receptors. Front Immunol. 2019;10:1958.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6718464</ArticleId><ArticleId IdType="pubmed">31507592</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EY, Mao T, Klein J, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pubmed">34010947</ArticleId></ArticleIdList></Reference><Reference><Citation>Woodruff MC, Ramonell RP, Nguyen DC, et al. Extrafollicular B cell responses correlate with neutralizing antibodies and morbidity in COVID-19. Nat Immunol. 2020;21:1506&#x2013;1516.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7739702</ArticleId><ArticleId IdType="pubmed">33028979</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and Important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J, Yuan X, Chen H, et al. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood. 2020;136:2080&#x2013;2089.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7596849</ArticleId><ArticleId IdType="pubmed">32877502</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q, Bastard P, Liu Z, et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020a;370.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7857407</ArticleId><ArticleId IdType="pubmed">32972995</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020;382:e38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7161262</ArticleId><ArticleId IdType="pubmed">32268022</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y, Nie HX, Hu K, et al. Abnormal immunity of non-survivors with COVID-19: predictors for mortality. Infect Dis Poverty. 2020;9:108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7396941</ArticleId><ArticleId IdType="pubmed">32746940</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y, Estes SK, Ali RA, et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med. 2020;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>